Rapid Micro Biosystems, Inc. posted strong FY25 revenue growth, driven by Growth Direct system placements, but remains unprofitable with a $47M net loss. RPID's growth hinges on large multi-system ...

The company reported Q1 2025 revenue of $7.2 million, reflecting a 28% increase compared to the previous year. Service revenue reached a quarterly record, growing 64% year-over-year. Gross margins ...

Robert Spignesi, CEO, opened by highlighting third quarter revenue of $7.8 million, which was above the midpoint of guidance and marked the twelfth consecutive quarter meeting or beating revenue ...

Additionally, Amgen will sponsor our first-ever North American Growth Direct Day in the second quarter. Product revenue increased 78% in the fourth quarter with outperformance driven by strong system ...

Rapid Micro Biosystems and Merck KGaA have signed a five-year global distribution agreement for Growth Direct systems and consumables. Rapid Micro Biosystems, Inc. has entered a five-year global ...

Rapid Micro Biosystems to announce Q4 and full year 2024 financial results on February 28, 2025. Webcast at 8:00 a.m. ET. Rapid Micro Biosystems, Inc. will announce its fourth quarter and full year ...

The new Rapid Sterility application includes a novel, proprietary test kit that has been developed for use with the Company’s fully automated Growth Direct system and delivers time to organism ...

LOWELL, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation ...

Amgen expands global Growth Direct system rollout with significant multi-system order in the fourth quarter 2025; will sponsor North American Growth Direct Day in the second quarter 2026 Samsung ...